123 related articles for article (PubMed ID: 25769206)
1. Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations.
Ho C; Rodig SJ
Semin Diagn Pathol; 2015 Sep; 32(5):381-91. PubMed ID: 25769206
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry 2015: Protein correlates of molecular alterations and predictive testing.
Hornick JL
Semin Diagn Pathol; 2015 Sep; 32(5):323-4. PubMed ID: 26250936
[No Abstract] [Full Text] [Related]
3. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
4. Unusual extramedullary hematopoietic neoplasms in lymph nodes.
Dayton VD; Williams SJ; McKenna RW; Linden MA
Hum Pathol; 2017 Apr; 62():13-22. PubMed ID: 28025076
[TBL] [Abstract][Full Text] [Related]
5. Soft tissue tumor pathology: New diagnostic immunohistochemical markers.
Doyle LA
Semin Diagn Pathol; 2015 Sep; 32(5):370-80. PubMed ID: 25726492
[TBL] [Abstract][Full Text] [Related]
6. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
7. A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies.
Zhang W; Yao J; Zhong M; Zhang Y; Guo X; Wang HY
Arch Pathol Lab Med; 2021 Nov; 145(11):1358-1366. PubMed ID: 34270703
[TBL] [Abstract][Full Text] [Related]
8. Interphase cytogenetics of hematological neoplasms under the perspective of the novel WHO classification.
Martín-Subero JI; Gesk S; Harder L; Grote W; Siebert R
Anticancer Res; 2003; 23(2A):1139-48. PubMed ID: 12820362
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
11. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
12. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
13. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.
Sukswai N; Khoury JD
Curr Hematol Malig Rep; 2019 Oct; 14(5):368-375. PubMed ID: 31338668
[TBL] [Abstract][Full Text] [Related]
15. Mutational determinants of epigenetic instablity in myeloid malignancies.
Jankowska AM; Szpurka H
Semin Oncol; 2012 Feb; 39(1):80-96. PubMed ID: 22289495
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic methods in the diagnosis of hematologic neoplasms.
Sen F; Vega F; Medeiros LJ
Semin Diagn Pathol; 2002 May; 19(2):72-93. PubMed ID: 12036283
[TBL] [Abstract][Full Text] [Related]
17. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations.
Bagg A
Hum Pathol; 2003 Apr; 34(4):352-8. PubMed ID: 12733115
[No Abstract] [Full Text] [Related]
19. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin.
Cesarman-Maus G; Braggio E; Lome-Maldonado C; Morales-Leyte AL; Fonseca R
Thromb Res; 2014 Apr; 133(4):606-9. PubMed ID: 24491425
[TBL] [Abstract][Full Text] [Related]
20. Molecular Diagnosis of Hematopoietic Neoplasms: 2018 Update.
Ramchandren R; Jazaerly T; Bluth MH; Gabali AM
Clin Lab Med; 2018 Jun; 38(2):293-310. PubMed ID: 29776632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
